Herbert M. Himmel
Herbert M. Himmel has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Michael Hoffmann
BPH-DD-ED-TOX, Safety Pharmacology, Bayer Pharma AG, Aprather Weg 18a, D-42096 Wuppertal, Germany
2 shared publications- T.M. Eriksson Faelker
Safety Pharmacology, Bayer AG, Aprather Weg 18a, 42096 Wuppertal, Germany
2 shared publications Alexandra Bussek
Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany
1 shared publication- Anke Rosch
Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Baden Wurttemberg 88397, Germany.
1 shared publication - Annie Delaunois
UCB Biopharma SRL , 1420 Braine-l’Alleud
1 shared publication Armando Lagrutta
Gene Tox and In Vitro Cellular Toxicology, Merck Research Laboratory, Merck & Co., Inc., United States
1 shared publication
Latest Publications
- Open Access
- 17 April 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 386 (1) , 26-34
Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat
Vericiguat and its metabolite M-1 were assessed for proarrhythmic risk in nonclinical in vitro and in vivo studies. In vitro manual voltage-clamp recordings at room temperature determined the effect of vericiguat on human Ether-a-go-go Related Gene (hERG) K+ channels. Effects of vericiguat and M-1 on hERG K+, Nav1.5, hCav1.2, hKvLQT1/1minK, and hKv4.3 channels were investigated via automated voltage-clamp recordings at ambient temperature. Effects of vericiguat and M-1 on hERG K+ and Nav1.5 channels at pathophysiological conditions were explored via manual voltage-clamp recordings at physiological temperature. Single oral doses of vericiguat (0.6, 2.0, and 6.0 mg/kg) were assessed for in vivo proarrhythmic risk via administration to conscious telemetered dogs; electrocardiogram (ECG) and hemodynamic parameters were monitored. ECG recordings were included in 4- and 39-week dog toxicity studies. In manual voltage-clamp recordings, vericiguat inhibited hERG K+-mediated tail currents in a concentration-dependent manner (20% threshold inhibitory concentration ~1.9 µM). In automated voltage-clamp recordings, neither vericiguat nor M-1 were associated with biologically relevant inhibition (>20%) of hNav1.5, hCav1.2, hKvLQT1, and hKv4.3. No clinically relevant observations were made for hNav1.5 and hKvLQT1 under simulated pathophysiological conditions. Vericiguat was associated with expected mode-of-action-related dose-dependent changes in systolic arterial blood pressure (up to −20%) and heart rate (up to +53%). At maximum vericiguat dose, corrected QT (QTc) interval changes from baseline varied slightly (−6 to +1%) depending on correction formula. Toxicity studies confirmed absence of significant QTc interval changes. There was no evidence of increased proarrhythmic risk from nonclinical studies with vericiguat or M-1. Significance Statement There was no evidence of increased proarrhythmic risk from in vitro and in vivo nonclinical studies with vericiguat or M-1. The integrated risk assessment of these nonclinical data combined with existing clinical data demonstrate administration of vericiguat 10 mg once daily in patients with heart failure with reduced ejection fraction is not associated with a proarrhythmic risk.
- 17 April 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 386 (1) , 26-34
Open AccessNonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat
Vericiguat and its metabolite M-1 were assessed for proarrhythmic risk in nonclinical in vitro and in vivo studies. In vitro manual voltage-clamp recordings at room temperature determined the effect of vericiguat on human Ether-a-go-go Related Gene (hERG) K+ channels. Effects of vericiguat and M-1 on hERG K+, Nav1.5, hCav1.2, hKvLQT1/1minK, and hKv4.3 channels were investigated via automated voltage-clamp recordings at ambient temperature. Effects of vericiguat and M-1 on hERG K+ and Nav1.5 channels at pathophysiological conditions were explored via manual voltage-clamp recordings at physiological temperature. Single oral doses of vericiguat (0.6, 2.0, and 6.0 mg/kg) were assessed for in vivo proarrhythmic risk via administration to conscious telemetered dogs; electrocardiogram (ECG) and hemodynamic parameters were monitored. ECG recordings were included in 4- and 39-week dog toxicity studies. In manual voltage-clamp recordings, vericiguat inhibited hERG K+-mediated tail currents in a concentration-dependent manner (20% threshold inhibitory concentration ~1.9 µM). In automated voltage-clamp recordings, neither vericiguat nor M-1 were associated with biologically relevant inhibition (>20%) of hNav1.5, hCav1.2, hKvLQT1, and hKv4.3. No clinically relevant observations were made for hNav1.5 and hKvLQT1 under simulated pathophysiological conditions. Vericiguat was associated with expected mode-of-action-related dose-dependent changes in systolic arterial blood pressure (up to −20%) and heart rate (up to +53%). At maximum vericiguat dose, corrected QT (QTc) interval changes from baseline varied slightly (−6 to +1%) depending on correction formula. Toxicity studies confirmed absence of significant QTc interval changes. There was no evidence of increased proarrhythmic risk from nonclinical studies with vericiguat or M-1. Significance Statement There was no evidence of increased proarrhythmic risk from in vitro and in vivo nonclinical studies with vericiguat or M-1. The integrated risk assessment of these nonclinical data combined with existing clinical data demonstrate administration of vericiguat 10 mg once daily in patients with heart failure with reduced ejection fraction is not associated with a proarrhythmic risk.
- 1 September 2019
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 99, 106588
Pupillary function test in rat: Establishment of imaging setup and pharmacological validation within modified Irwin test
- 1 September 2019
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 99, 106588
Pupillary function test in rat: Establishment of imaging setup and pharmacological validation within modified Irwin test
- 1 September 2019
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 99, 106571
Variability of non-clinical behavioral CNS safety assessment: An intercompany comparison
- 1 September 2019
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 99, 106571
Variability of non-clinical behavioral CNS safety assessment: An intercompany comparison
- 1 September 2016
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 81, 313-322
The “induced hyperactivity” test for the de-risking of potential off-target activity of antihypertensive drugs
- 1 September 2016
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 81, 313-322
The “induced hyperactivity” test for the de-risking of potential off-target activity of antihypertensive drugs
- 1 July 2013
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 68 (1) , 97-111
Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds
- 1 July 2013
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 68 (1) , 97-111
Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds
- 10 April 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 166 (1) , 276-296
Field and action potential recordings in heart slices: correlation with establishedin vitroandin vivomodels
BACKGROUND AND PURPOSEAction potential (AP) recordings inex vivoheart preparations constitute an important component of the preclinical cardiac safety assessment according to the ICH S7B guideline. Most AP measurement models are sensitive, predictive and informative but suffer from a low throughput. Here, effects of selected anti‐arrhythmics (flecainide, quinidine, atenolol, sotalol, dofetilide, nifedipine, verapamil) on field/action potentials (FP/AP) of guinea pig and rabbit ventricular slices are presented and compared with data from establishedin vitroandin vivomodels.EXPERIMENTAL APPROACHData from measurements of membrane currents (hERG, INa), AP/FP (guinea pig and rabbit ventricular slices), AP (rabbit Purkinje fibre), haemodynamic/ECG parameters (conscious, telemetered dog) were collected, compared and correlated to complementary published data (focused literature search).KEY RESULTSThe selected anti‐arrhythmics, flecainide, quinidine, atenolol, sotalol, dofetilide, nifedipine and verapamil, influenced the shape of AP/FP of guinea pig and rabbit ventricular slices in a manner similar to that observed for rabbit PF. The findings obtained from slice preparations are in line with measurements of membrane currentsin vitro, papillary muscle APin vitroand haemodynamic/ECG parameters from conscious dogsin vivo, and were also corroborated by published data.CONCLUSION AND IMPLICATIONSFP and AP recordings from heart slices correlated well with establishedin vitroandin vivomodels in terms of pharmacology and predictability. Heart slice preparations yield similar results as papillary muscle but offer enhanced throughput for mechanistic investigations and may substantially reduce the use of laboratory animals.
- 10 April 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 166 (1) , 276-296
Field and action potential recordings in heart slices: correlation with establishedin vitroandin vivomodels
BACKGROUND AND PURPOSEAction potential (AP) recordings inex vivoheart preparations constitute an important component of the preclinical cardiac safety assessment according to the ICH S7B guideline. Most AP measurement models are sensitive, predictive and informative but suffer from a low throughput. Here, effects of selected anti‐arrhythmics (flecainide, quinidine, atenolol, sotalol, dofetilide, nifedipine, verapamil) on field/action potentials (FP/AP) of guinea pig and rabbit ventricular slices are presented and compared with data from establishedin vitroandin vivomodels.EXPERIMENTAL APPROACHData from measurements of membrane currents (hERG, INa), AP/FP (guinea pig and rabbit ventricular slices), AP (rabbit Purkinje fibre), haemodynamic/ECG parameters (conscious, telemetered dog) were collected, compared and correlated to complementary published data (focused literature search).KEY RESULTSThe selected anti‐arrhythmics, flecainide, quinidine, atenolol, sotalol, dofetilide, nifedipine and verapamil, influenced the shape of AP/FP of guinea pig and rabbit ventricular slices in a manner similar to that observed for rabbit PF. The findings obtained from slice preparations are in line with measurements of membrane currentsin vitro, papillary muscle APin vitroand haemodynamic/ECG parameters from conscious dogsin vivo, and were also corroborated by published data.CONCLUSION AND IMPLICATIONSFP and AP recordings from heart slices correlated well with establishedin vitroandin vivomodels in terms of pharmacology and predictability. Heart slice preparations yield similar results as papillary muscle but offer enhanced throughput for mechanistic investigations and may substantially reduce the use of laboratory animals.